novel regimens with alternative agents for immunosuppression and cytotoxicity worthy of study. Ifosfamide has potent antitumor effects even when cliniSuccessful allogeneic hematopoietic transplants require conditioning regimens with sufficient immunosupprescal resistance to cyclophosphamide exists. 5 Recent data stress the importance of a dose-response relationship for sion to allow acceptance of the allograft. Cyclophosphamide, in combination either with TBI or with chemthe cytotoxic effects of ifosfamide. 6, 7 The toxicity profile of ifosfamide allows considerable dose escalation before otherapeutic drugs, is the keystone of commonly used regimens. The toxicities of TBI and tumor resistance to reaching intolerable non-hematopoietic side-effects. Preclinical studies in the busulfan-treated rat document that cyclophosphamide create a niche for alternative, chemotherapy-based conditioning regimens. We report sucifosfamide is sufficiently immunosuppressive to permit the allografting of hematopoietic stem cells. 8, 9 The cytotoxic cessful allogeneic stem cell transplantation after an ifosfamide-based regimen with ifosfamide 20 g/m 2 , and immunosuppressive properties make ifosfamide an excellent agent for chemotherapy-based conditioning carboplatin 1.8 g/m 2 and etoposide 3 g/m 2 (ICE) in divided doses over 6 days. Engraftment was prompt with regimens. We report successful allogeneic stem cell transplantation neutrophils у20 × 10 9 /l on day +10 and platelets Ͼ20 × 10 9 /l on day +18. Engraftment of donor cells was following conditioning with ifosfamide, plus carboplatin and etoposide (ICE). The latter two agents have weak documented by chromosome analysis and by VNTR analysis. An ifosfamide-based regimen provides sufimmunosuppressive properties which make a minor contribution to the immunosuppressive component of the ficient immunosuppression for hematopoietic allograft acceptance in the absence of cyclophosphamide or of regimen.
, and immunosuppressive properties make ifosfamide an excellent agent for chemotherapy-based conditioning carboplatin 1.8 g/m 2 and etoposide 3 g/m 2 (ICE) in divided doses over 6 days. Engraftment was prompt with regimens. We report successful allogeneic stem cell transplantation neutrophils у20 × 10 9 /l on day +10 and platelets Ͼ20 × 10 9 /l on day +18. Engraftment of donor cells was following conditioning with ifosfamide, plus carboplatin and etoposide (ICE). The latter two agents have weak documented by chromosome analysis and by VNTR analysis. An ifosfamide-based regimen provides sufimmunosuppressive properties which make a minor contribution to the immunosuppressive component of the ficient immunosuppression for hematopoietic allograft acceptance in the absence of cyclophosphamide or of regimen. model shows a dose-dependent relationship between the Her brother, an HLA-identical sibling, received G-CSF ifosfamide dose and the acceptance of a bone marrow allo-10 g/kg s.c. daily for 5 days and underwent leukapheresis graft. 8, 9 Neither single agent carboplatin nor single agent using a Fenwall CS300 apparatus on days 4, 5 and 6. The etoposide is sufficiently immunosuppressive to promote combined products from day 4 and 5 were infused on transallograft acceptance. 8, 9 However, recent evidence in plant day 0. The third apheresis product was infused on humans suggests that allografting after busulfan and day +1. We did not perform T cell depletion. Graft-versussteroids is possible.
11
host disease (GVHD) prophylaxis was cyclosporin A (CsA) Cyclophosphamide used as a single agent or in combi-5 mg/kg continuous i.v. infusion on day −3 and then 3 nation with other chemotherapy drugs, or in combination mg/kg/day i.v. in two divided doses. CsA doses were with TBI can promote allograft acceptance. 1,2,12 However, adjusted as needed to maintain levels at 300 g/ml accordtumor resistance to cyclophosphamide may limit the cytoing to a monoclonal antibody method which assays the partoxic effect. Ifosfamide has shown antitumor activity in the ent compound. Both the donor and the recipient signed presence of resistance to cyclophosphamide. 5 This property informed consent forms approved by the local Institutional makes ifosfamide a rational alternative to cyclophosphamReview Board.
ide for selected patients undergoing allogeneic hematopoietic cell transplantation. Predominant non-hematopoietic toxicities of the ICE regimen are mucositis and renal insufficiency. 10 We have reported recently a regimen with propantheline, which Results reduced the mucositis after ICE to WHO grade 0-2 in 90% of patients. 13 This supportive care measure makes the ICE regimen much less toxic and might be compatible with a The donor's peripheral white blood cell count rose from GVHD prophylaxis regimen with methotrexate. The transi-6.2 × 10 9 /l to 43.6 × 10 9 /l on the fourth day of G-CSF ent non-oliguric renal failure observed in our patient may administration. Total cell yields expressed as cells/kg of represent regimen-related toxicity. The prior treatment with recipient weight were: mononuclear cells, 9.8 × 10 8 cisplatinum may have predisposed our patient to more sevcells/kg; CD34 + cells, 14.1 × 10 6 cells/kg; CFU-GM, ere renal damage. An alternative explanation for the renal 8 × 10 5 colony-forming cells/kg. Donor toxicity was limited insufficiency is an interaction between CsA and the ICE to mild bone pain and lethargy.
regimen. Both ifosfamide and carboplatin can compromise The patient developed a sustained absolute neutrophil renal function and the addition of CsA could amplify the count (ANC) Ͼ0.5 × 10 9 /l on day +10 and an ANC toxicity. Further clinical study is necessary to determine Ͼ1 × 10 9 /l on day +11. The platelet count exceeded 20 ϫ whether or not there is a nephrotoxic drug interaction 10 9 /l on day +18. Chromosome studies performed on day between CsA and ifosfamide. It is worth noting that renal +34 bone marrow aspirate had an XY karyotype in 100% insufficiency (creatinine Ͼ2.0 mg/dl) in the autograft setof the cells. Molecular studies using the VNTR technique ting has become rare since we began hyperhydration (у250 documented the donor origin of the marrow cells. Histocm 3 normal saline/h). It is possible that hyperhydration, logic evaluation did not show metastatic cancer cells in the perhaps in combination with new agents such as amifostine, marrow specimen. The patient never developed any clinical can further reduce the risk of renal impairment. 14 evidence of acute or chronic GVHD. Additional study is needed to define the advantages, if There was no toxicity associated with the stem cell any, of the ICE regimen over other conditioning regimens; infusions. Other clinical toxicities included WHO grade IV to minimize toxicity; and to determine the immunologic oral mucositis, enteritis, and non-oliguric renal insufeffects of allografts upon solid tumors. Our program is ficiency. The serum creatinine rose from a pretransplant continuing to develop protocols in these areas. level of 0.8 mg/dl to a peak of 4.5 mg/dl on day +6. The serum creatinine declined to a plateau of 1.7 mg/dl by day +38. She suffered transient neutropenia and thrombocytoReferences penia associated with ganciclovir administered for cytomegalovirus prophylaxis. The blood counts recovered to only and died 1 week later.
